Defining Primary Sclerosing Cholangitis: Results From an International Primary Sclerosing Cholangitis Study Group Consensus Process

PSC Study Group

doi:10.1053/j.gastro.2021.07.046

Defining Primary Sclerosing Cholangitis: Results From an International Primary Sclerosing Cholangitis Study Group Consensus Process

PSC Study Group

Amsterdam UMC - University of Amsterdam
Yale University
University of Oslo
ERN RARE Liver, Hamburg, Germany
University of California at Davis
Primary Children's Medical Center
University College London
University of Helsinki
Mayo Clinic Rochester, MN
Heidelberg University
University of Birmingham

Research output: Contribution to journal › Article › Academic › peer-review

Original language	English
Pages (from-to)	1764-1775.e5
Journal	Gastroenterology
Volume	161
Issue number	6
DOIs	https://doi.org/10.1053/j.gastro.2021.07.046
Publication status	Published - 1 Dec 2021

Access to Document

10.1053/j.gastro.2021.07.046

Cite this

@article{96f7e738831347069ac5e28905f14e94,

title = "Defining Primary Sclerosing Cholangitis: Results From an International Primary Sclerosing Cholangitis Study Group Consensus Process",

author = "Ponsioen, \{Cyriel Y.\} and Assis, \{David N.\} and Boberg, \{Kirsten M.\} and Bowlus, \{Christopher L.\} and Mark Deneau and Douglas Thorburn and Lars Aabakken and Martti F{\"a}rkkil{\"a} and Bret Petersen and Christian Rupp and \{PSC Study Group\} and H{\"u}bscher, \{Stefan G.\}",

note = "Funding Information: Conflicts of interest These authors disclose the following: Cyriel Y. Ponsioen has received research grant funding from Takeda, advisory fees from Pliant and Shire, and speaker{\textquoteright}s fees from Takeda and Tillotts. Christopher L. Bowlus has received research grants from Takeda, Bristol Myers Squibb, Cymabay, Intercept, Gilead, Genfit, BiomX, Pliant, Novartis, GlaxoSmithKline, and Mirium and advisory fees from GlaxoSmithKline, Gilead, BiomX, and Mirium. Bret Petersen has received consultancy fees from Olympus, Pentax, and Boston Scientific and grant funding from Boston Scientific. Stefan G. H{\"u}bscher has received consultancy fees from Dr Falk Pharma. The remaining authors disclose no conflicts.",

year = "2021",

month = dec,

day = "1",

doi = "10.1053/j.gastro.2021.07.046",

language = "English",

volume = "161",

pages = "1764--1775.e5",

journal = "Gastroenterology",

issn = "0016-5085",

publisher = "W.B. Saunders Ltd",

number = "6",

}

TY - JOUR

T1 - Defining Primary Sclerosing Cholangitis

T2 - Results From an International Primary Sclerosing Cholangitis Study Group Consensus Process

AU - Ponsioen, Cyriel Y.

AU - Assis, David N.

AU - Boberg, Kirsten M.

AU - Bowlus, Christopher L.

AU - Deneau, Mark

AU - Thorburn, Douglas

AU - Aabakken, Lars

AU - Färkkilä, Martti

AU - Petersen, Bret

AU - Rupp, Christian

AU - PSC Study Group

AU - Hübscher, Stefan G.

N1 - Funding Information: Conflicts of interest These authors disclose the following: Cyriel Y. Ponsioen has received research grant funding from Takeda, advisory fees from Pliant and Shire, and speaker’s fees from Takeda and Tillotts. Christopher L. Bowlus has received research grants from Takeda, Bristol Myers Squibb, Cymabay, Intercept, Gilead, Genfit, BiomX, Pliant, Novartis, GlaxoSmithKline, and Mirium and advisory fees from GlaxoSmithKline, Gilead, BiomX, and Mirium. Bret Petersen has received consultancy fees from Olympus, Pentax, and Boston Scientific and grant funding from Boston Scientific. Stefan G. Hübscher has received consultancy fees from Dr Falk Pharma. The remaining authors disclose no conflicts.

PY - 2021/12/1

Y1 - 2021/12/1

UR - https://www.scopus.com/pages/publications/85119256195

U2 - 10.1053/j.gastro.2021.07.046

DO - 10.1053/j.gastro.2021.07.046

M3 - Article

C2 - 34384749

SN - 0016-5085

VL - 161

SP - 1764-1775.e5

JO - Gastroenterology

JF - Gastroenterology

IS - 6

ER -

Defining Primary Sclerosing Cholangitis: Results From an International Primary Sclerosing Cholangitis Study Group Consensus Process

Access to Document

Other files and links

Cite this